CABA peer analysis
Cabaletta Bio (CABA) against its competitors: price, today's move, 1-year return and market value side by side.
CABA and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALLO Allogene Therapeutics | $1.07 | 3.37% | 2.38% | $371.40M |
| AVIR Atea Pharmaceuticals | $4.42 | 2.55% | 36.00% | $354.50M |
| CAPR Capricor | $9.82 | 9.11% | 57.88% | $570.92M |
| EDIT Editas Medicine | $2.75 | 7.20% | 2.42% | $423.11M |
| HUMA Humacyte | $0.46 | 1.99% | -65.11% | $126.98M |
| IMMP Immutep | $3.34 | 24.16% | -91.30% | $24.62M |
| KYTX Kyverna Therapeutics | $5.17 | 5.94% | -27.08% | $319.73M |
| LXEO Lexeo Therapeutics | $3.15 | 8.82% | -62.65% | $258.17M |
| LYEL Lyell Immunopharma | $15.45 | 3.97% | -13.59% | $379.85M |
| PRQR ProQR Therapeutics | $1.38 | 2.22% | -37.56% | $145.40M |
| CABA Cabaletta Bio | $1.50 | 15.00% | -39.72% | $322.50M |
- CABA's peers: ALLO (Allogene Therapeutics), AVIR (Atea Pharmaceuticals), CAPR (Capricor), EDIT (Editas Medicine), HUMA (Humacyte), IMMP (Immutep), KYTX (Kyverna Therapeutics), LXEO (Lexeo Therapeutics).
Updated 2026-11-10 04:46 UTC